Matinas Biopharma (MTNB) Short Interest Ratio & Short Volume $0.87 +0.05 (+6.10%) As of 11:40 AM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Matinas Biopharma Short Interest DataMatinas Biopharma (MTNB) has a short interest of 88,600 shares, representing 1.94% of the float (the number of shares available for trading by the public). This marks a 9.38% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.2, indicating that it would take 1.2 days of the average trading volume of 333,747 shares to cover all short positions.Current Short Interest88,600 sharesPrevious Short Interest81,000 sharesChange Vs. Previous Month+9.38%Dollar Volume Sold Short$68,222.00Short Interest Ratio1.2 Days to CoverLast Record DateMay 15, 2025Outstanding Shares5,087,000 sharesFloat Size4,560,000 sharesShort Percent of Float1.94%Today's Trading Volume3,048,528 sharesAverage Trading Volume333,747 sharesToday's Volume Vs. Average913% Short Selling Matinas Biopharma? Sign up to receive the latest short interest report for Matinas Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMTNB Short Interest Over TimeMTNB Days to Cover Over TimeMTNB Percentage of Float Shorted Over Time Matinas Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202588,600 shares $68,222.00 +9.4%1.9%1.2 $0.77 4/30/202581,000 shares $47,871.00 -58.3%1.8%0.6 $0.59 4/15/2025194,400 shares $112,752.00 -2.5%4.3%1.4 $0.58 3/14/2025232,400 shares $127,587.60 -20.4%5.1%0.5 $0.55 2/14/2025348,200 shares $212,158.26 +17.0%7.3%0.8 $0.61 1/31/2025297,600 shares $172,608.00 -56.4%6.3%0.6 $0.58 1/15/2025683,100 shares $399,955.05 +518.2%14.5%1.3 $0.59 10/31/202432,400 shares $0.00 -59.7%0.7%0.2 $0.00 10/15/202480,400 shares $0.00 +28.2%1.6%2 $0.00 9/30/202462,700 shares $0.00 -20.3%1.3%1.6 $0.00 Get the Latest News and Ratings for MTNB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter. 9/15/202478,700 shares $0.00 +36.4%1.6%2.4 $0.00 8/31/202457,700 shares $0.00 -95.6%1.2%1.9 $0.00 8/15/20241,310,000 shares $0.00 -4.4%N/A1.2 $0.00 7/31/20241,370,000 shares $0.00 -27.9%N/A1.6 $0.00 7/15/20241,900,000 shares $0.00 -15.2%N/A2 $0.00 6/30/20242,240,000 shares $0.00 +6.7%N/A2.5 $0.00 6/15/20242,100,000 shares $0.00 -11.0%N/A1.3 $0.00 5/31/20242,360,000 shares $0.00 No ChangeN/A1.5 $0.00 5/15/20242,360,000 shares $0.00 -27.2%N/A1.4 $0.00 4/30/20243,240,000 shares $0.00 +1.6%N/A2 $0.00 4/15/20243,190,000 shares $0.00 -2.5%N/A2.1 $0.00 3/31/20243,270,000 shares $0.00 +147.7%N/A2.2 $0.00 3/15/20241,320,000 shares $0.00 -10.2%N/A1 $0.00 2/29/20241,470,000 shares $0.00 +22.5%N/A1.5 $0.00 2/15/20241,200,000 shares $0.00 -15.5%N/A1.2 $0.00 1/31/20241,420,000 shares $0.00 +8.4%N/A1 $0.00 1/15/20241,310,000 shares $0.00 -36.4%N/A0.8 $0.00 12/31/20232,060,000 shares $0.00 -10.0%N/A0.2 $0.00 12/15/20232,290,000 shares $0.00 -34.4%N/A0.2 $0.00 11/30/20233,490,000 shares $0.00 -21.6%N/A0.4 $0.00 11/15/20234,450,000 shares $0.00 -2.8%N/A0.5 $0.00 10/31/20234,580,000 shares $0.00 -23.9%N/A0.5 $0.00 10/15/20236,020,000 shares $0.00 +3,030.5%N/A0.7 $0.00 9/30/2023192,300 shares $0.00 -31.0%N/A0.2 $0.00 9/15/2023278,500 shares $0.00 -60.9%N/A0.4 $0.00 8/31/2023711,500 shares $0.00 -38.1%N/A1.1 $0.00 8/15/20231,150,000 shares $0.00 -24.8%N/A1.7 $0.00 7/31/20231,530,000 shares $0.00 +11.7%N/A3.2 $0.00 7/15/20231,370,000 shares $0.00 -14.4%N/A2.8 $0.00 6/30/20231,600,000 shares $576,000.00 +4.6%N/A2.9 $0.36Why July 22nd Could Mean Big Changes for Social Security (Ad)In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Social Security — and his plan is set to roll out July 22. What's coming next isn't about trimming waste.To see the full playbook and how it could impact everyone, click here. 6/15/20231,530,000 shares $0.00 +25.4%N/A3 $0.00 5/31/20231,220,000 shares $0.00 -12.9%N/A2.5 $0.00 5/15/20231,400,000 shares $0.00 -14.1%N/A3.2 $0.00 4/30/20231,630,000 shares $0.00 +48.2%N/A4.4 $0.00 4/15/20231,100,000 shares $0.00 -9.8%N/A3 $0.00 3/31/20231,220,000 shares $0.00 +8.9%N/A4.4 $0.00 3/15/20231,120,000 shares $0.00 -26.8%N/A3.6 $0.00 2/28/20231,530,000 shares $0.00 +10.1%N/A3.9 $0.00 2/15/20231,390,000 shares $0.00 -6.1%N/A3.5 $0.00 1/31/20231,480,000 shares $0.00 +5.0%N/A3.8 $0.00 1/15/20231,410,000 shares $0.00 -2.1%N/A3.2 $0.00 12/30/20221,440,000 shares $720,000.00 -23.4%N/A3.4 $0.50 12/15/20221,880,000 shares $0.00 +20.5%N/A4.7 $0.00 11/30/20221,560,000 shares $0.00 -2.5%N/A4.7 $0.00 11/15/20221,600,000 shares $0.00 -3.0%N/A5.8 $0.00 10/31/20221,650,000 shares $1.29 million +2.5%N/A5.4 $0.78 10/15/20221,610,000 shares $0.00 -6.4%N/A5.1 $0.00 9/30/20221,720,000 shares $0.00 +1.2%N/A5.8 $0.00 9/15/20221,700,000 shares $0.00 +6.3%N/A5 $0.00 8/31/20221,600,000 shares $1.14 million +1.9%N/A4.3 $0.71 8/15/20221,570,000 shares $0.00 -5.4%N/A4.1 $0.00 7/31/20221,660,000 shares $0.00 -7.3%N/A4.1 $0.00 7/15/20221,790,000 shares $0.00 -16.7%N/A4.1 $0.00 6/30/20222,150,000 shares $0.00 -16.7%N/A4 $0.00 6/15/20222,580,000 shares $0.00 -1.5%N/A4.5 $0.00 5/31/20222,620,000 shares $1.87 million -11.5%N/A4.2 $0.72 5/15/20222,960,000 shares $0.00 +7.3%N/A4.4 $0.00 4/30/20222,760,000 shares $0.00 -9.2%N/A4.2 $0.00 4/15/20223,040,000 shares $0.00 +9.4%N/A4 $0.00 3/31/20222,780,000 shares $2.24 million +4.9%N/A4 $0.80 3/15/20222,650,000 shares $0.00 -4.7%N/A3.7 $0.00 2/28/20222,780,000 shares $1.60 million -8.3%N/A3.3 $0.57 2/15/20223,030,000 shares $0.00 -10.1%N/A3.3 $0.00 1/31/20223,370,000 shares $2.53 million -5.9%N/A3 $0.75 1/15/20223,580,000 shares $0.00 -2.5%N/A3 $0.00 12/31/20213,670,000 shares $3.71 million +11.2%N/A2.9 $1.01 12/15/20213,300,000 shares $0.00 +13.0%N/A1.9 $0.00 11/30/20212,920,000 shares $0.00 +7.0%N/A1.2 $0.00 11/15/20212,730,000 shares $0.00 -10.5%N/A1.1 $0.00 10/29/20213,050,000 shares $3.39 million +4.1%N/A1.3 $1.11 10/15/20212,930,000 shares $0.00 -1.4%N/A1.3 $0.00 9/30/20212,970,000 shares $0.00 -13.9%N/A1.4 $0.00 9/15/20213,450,000 shares $0.00 +14.6%N/A1.9 $0.00 8/31/20213,010,000 shares $0.00 -16.2%N/A2.8 $0.00 8/13/20213,590,000 shares $0.00 +2.0%N/A3.3 $0.00 7/30/20213,520,000 shares $0.00 -76.6%1.8%3.2 $0.00 7/15/202115,030,000 shares $0.00 -1.7%7.7%13 $0.00 6/30/202115,290,000 shares $0.00 -1.2%8.3%11.9 $0.00 6/15/202115,470,000 shares $0.00 +0.3%8.4%11.6 $0.00 5/28/202115,420,000 shares $0.00 -0.7%8.3%11.9 $0.00Why July 22nd Could Mean Big Changes for Social Security (Ad)In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Social Security — and his plan is set to roll out July 22. What's coming next isn't about trimming waste.To see the full playbook and how it could impact everyone, click here. 5/14/202115,530,000 shares $0.00 +0.2%N/A10.1 $0.00 4/30/202115,500,000 shares $0.00 +0.9%N/A6.4 $0.00 4/15/202115,370,000 shares $13.22 million -2.9%N/A4.2 $0.86 3/31/202115,830,000 shares $14.41 million +0.3%N/A3.9 $0.91 3/15/202115,790,000 shares $15.95 million +1.7%N/A2.7 $1.01 2/26/202115,520,000 shares $16.30 million -7.8%N/A2.5 $1.05 2/12/202116,830,000 shares $20.87 million +9.1%N/A2.7 $1.24 1/29/202115,430,000 shares $21.14 million -4.7%N/A2.7 $1.37 1/15/202116,190,000 shares $24.12 million +0.3%N/A3.7 $1.49 12/31/202016,140,000 shares $23.73 million -1.7%N/A4 $1.47 12/15/202016,410,000 shares $17.72 million +0.6%N/A8.2 $1.08 11/30/202016,320,000 shares $17.14 million -1.1%N/A8.5 $1.05 11/15/202016,500,000 shares $13.25 million -1.2%N/A10.6 $0.80 10/30/202016,700,000 shares $14.24 million +1.1%N/A9.4 $0.85 10/15/202016,520,000 shares $14.70 million -2.0%N/A7.7 $0.89 9/30/202016,850,000 shares $12.91 million +3.4%N/A6.5 $0.77 9/15/202016,300,000 shares $12.61 million +0.6%N/A6.2 $0.77 8/31/202016,210,000 shares $12.68 million -1.7%N/A6.2 $0.78 8/14/202016,490,000 shares $13.61 million +2.0%N/A6.5 $0.83 7/31/202016,160,000 shares $12.64 million +5.7%N/A6.4 $0.78 7/15/202015,290,000 shares $11.47 million +8.6%N/A7.2 $0.75 6/30/202014,080,000 shares $11.15 million +0.3%N/A8 $0.79 6/15/202014,040,000 shares $11.50 million -0.5%N/A7.6 $0.82 MTNB Short Interest - Frequently Asked Questions What is Matinas Biopharma's current short interest? Short interest is the volume of Matinas Biopharma shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 88,600 shares of MTNB short. 1.94% of Matinas Biopharma's shares are currently sold short. Learn More on Matinas Biopharma's current short interest. What is a good short interest ratio for Matinas Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MTNB shares currently have a short interest ratio of 1.0. Learn More on Matinas Biopharma's short interest ratio. What is a good short interest percentage for Matinas Biopharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.94% of Matinas Biopharma's floating shares are currently sold short. Is Matinas Biopharma's short interest increasing or decreasing? Matinas Biopharma saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 88,600 shares, an increase of 9.4% from the previous total of 81,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Matinas Biopharma's float size? Matinas Biopharma currently has issued a total of 5,087,000 shares. Some of Matinas Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Matinas Biopharma currently has a public float of 4,560,000 shares. How does Matinas Biopharma's short interest compare to its competitors? 1.94% of Matinas Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Matinas Biopharma: DURECT Co. (2.88%), NKGen Biotech, Inc. (0.30%), Bullfrog AI Holdings, Inc. (4.89%), Marker Therapeutics, Inc. (1.61%), GeoVax Labs, Inc. (8.73%), ProMIS Neurosciences, Inc. (0.61%), ProPhase Labs, Inc. (1.22%), Leap Therapeutics, Inc. (6.15%), MEI Pharma, Inc. (0.03%), AlloVir, Inc. (2.56%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short Matinas Biopharma stock? Short selling MTNB is an investing strategy that aims to generate trading profit from Matinas Biopharma as its price is falling. MTNB shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Matinas Biopharma? A short squeeze for Matinas Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MTNB, which in turn drives the price of the stock up even further. How often is Matinas Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MTNB, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies DURECT Short Interest NKGen Biotech Short Interest Bullfrog AI Short Interest Marker Therapeutics Short Interest GeoVax Labs Short Interest ProMIS Neurosciences Short Interest ProPhase Labs Short Interest Leap Therapeutics Short Interest MEI Pharma Short Interest AlloVir Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:MTNB) was last updated on 6/3/2025 by MarketBeat.com Staff From Our PartnersDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.